Zenocutuzumab OK’d for NRG1 Fusion+ Cholangiocarcinoma

Published Date: 13 May 2026

The bispecific antibody has previously granted accelerated approval for advanced, unresectable, or metastatic non-small cell lung cancer and pancreatic adenocarcinoma harboring the gene fusions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

2.

Is global cancer care losing its human touch?

3.

New study links air pollution with higher rates of head and neck cancer

4.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

5.

Avoiding Neuropathy From Chemo; Predictive Value of Screening EKGs


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot